Contact this trialFirst, we need to learn more about you.
Atypical Antipsychotic
Lumateperone for Schizophrenia and Bipolar Disorder
Recruiting2 awardsPhase 3
Orlando, Florida
This trial is being conducted at multiple locations worldwide and will last for 26 weeks. It aims to evaluate the safety and tolerability of lumateperone in children with schizophrenia or bipolar disorder.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.